Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-label Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LUCAR-G39D, a Dual-targeted Cell Preparation Targeting CD19/CD20, in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

NCT06395870 is registered in ClinicalTrials.gov with Tianjin Medical University Cancer Institute and Hospital as lead sponsor.

NCT NCT06395870
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06395870 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-label Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LUCAR-G39D, a Dual-targeted Cell Preparation Targeting CD19/CD20, in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Lead sponsor
Tianjin Medical University Cancer Institute and Hospital
Phase
Phase 1
Overall status
Recruiting
Start date
May 9, 2024
Completion date
June 30, 2028
Enrollment
33 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell non-hodgkin lymphoma-recurrent, b-cell non-hodgkin lymphoma-refractory